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Abstract 
Objective: Attention deficit hyperactivity disorder (ADHD) is a costly public health problem. To 
the authors’ knowledge, this is the first study on the cost-effectiveness of the major forms of ADHD 
treatments used in NIMH’s Multimodal Treatment Study of Children With ADHD (MTA Study). 
Method: Five hundred seventy-nine children with ADHD, combined type, ages 7 to 9.9, were 
assigned to 14 months of medication management, behavioral treatment, both combined, or community 
care. Services were tallied throughout the study, including medication, health care visits, behavioral 
treatments, and rental costs. Provider specialty, total time, and number of visits with providers were used to 
calculate costs, adjusted to FY 2000 dollars with the consumer price index. 
Results: Treatment costs varied fourfold, with medication management being the least expensive, 
followed by behavioral treatment, and then combined treatment. Lower costs of medication treatment were 
found in the community care group, reflecting the less intensive (and less effective) nature of 
community-delivered treatment. Medical management was more effective but more costly than community 
care and more cost-effective than combination treatment and behavioral treatment alone. Under some 
conditions, combination treatment (medical management and psychotherapy) were somewhat more 
cost-effective, as demonstrated by lower costs per additional child “normalized” among children with 
multiple comorbid disorders. 
Conclusions: Medical management treatment, although not as effective as combined medical 
management and behavioral treatment, is likely to be more cost-effective in routine treatment for children 
with ADHD, particularly those without comorbid disorders. For some children with comorbid disorders, it 
may be cost-effective to provide combination treatment. 
Attention deficit hyperactivity disorder (ADHD) is the most prevalent behavioral disorder 
in children (1) and represents a costly major public health problem. Without effective treatments, 
difficulties experienced by children with ADHD may continue or even increase into adulthood, 
resulting in possible justice system contacts and substance abuse troubles (2), as well as effects 
on ultimate rates of child abuse, crime, adult mental illness, and accidents with severe injuries (3, 
4). Although use and treatment rates are increasing, little is known about the cost of these 
treatments and services for children or the overall financial impact on society (2). Economic 
studies of mental health services are rare in the literature and are especially scarce for specific 
children’s disorders, such as ADHD (3).  
In a study specifically related to ADHD, Kelleher et al. (5) examined the costs of this 
disorder within a Medicaid population, finding that pharmaceutical costs were 42% higher for 
children with ADHD than for those with a similarly prevalent comparison condition—asthma. 
Similarly, in the first study to provide national estimates, Chan et al. (6) found that the 
differences in costs between ADHD and asthma were statistically significant only for 
prescription-related costs and out-of-pocket expenses, with ADHD incurring higher costs. 
Swensen and colleagues (7) studied the resource use of insured patients with ADHD and their 
family members and found that the average annual medical costs per family member were 
approximately double for ADHD families compared to matched comparison families ($2,461 
versus $1,220, respectively). Also, costs for the family member with ADHD were three times 
higher than those for comparison subjects ($2,128 versus $741). Notably, only 13% of the costs 
for patients with ADHD were attributable to treatment of the disorder, possibly because most of 
them were not regularly receiving treatment. 
In examining the health care records of nearly 5,000 children over a 9-year period, 
Leibson et al. (8) noted the difference in health care use and costs between children with and 
without ADHD. Cost analyses indicated that all types of medical bills were higher for children 
with ADHD in all of the 9 years. The median costs for children with ADHD were more than 
double those without ADHD ($4,306 versus $1,944). 
The presence of an accompanying clinical diagnosis (in addition to ADHD) can exert 
substantial effects on the cost of treatment. For example, Guevara et al. (9) compared the health 
care costs and use between children with and without ADHD in a retrospective matched cohort 
study. Approximately 30% of all children with ADHD in their study were diagnosed with a 
coexisting mental health disorder. This comorbidity entailed additional costs of $437 per child 
($812 versus $375) for total health care services in comparison to the children with ADHD but 
no comorbidity. This effect of comorbidity on costs is common throughout the literature (10) and 
may denote the need for differential treatments to reduce expenses and reach better treatment 
outcomes. Although these studies illuminate the burden of illness associated with ADHD, no 
studies, to our knowledge, have addressed the cost and cost-effectiveness of specific treatments 
for ADHD in the United States. 
International analyses have been rare, too. In a report commissioned by the Canadian 
Coordinating Office for Health Technology Assessment, Miller et al. (11) compared six 
treatments: methylphenidate, dexamphetamine, pemoline (high-dose and low-dose), nondrug 
therapy, combined therapy, and no treatment, adopting a 1-year time horizon and the perspective 
of third-party payers. Based on a systematic review of the literature (12), treatment effects were 
determined by the Conners’ Teachers Rating Scale. The methylphenidate strategy was found to 
dominate its alternatives, with a cost of $498 (Canadian) per 6-point (or one standard deviation) 
improvement in score on the Conners’ Teachers Rating Scale. It should be noted here that 
effectiveness data for the psychological/ behavioral (nondrug) and the combination strategies 
were based on fewer than 20 patients each, resulting in widely associated 95% confidence 
intervals, translating into corresponding uncertainty of the economic evaluation presented. In the 
United Kingdom, Gilmore and Milne (13) found, from the perspective of the National Health 
Service, that methylphenidate was cost-effective in children with hyperkinetic disorder, 
according to ICD-10 criteria. This study considered neither behavioral nor combined treatment 
strategies, however. Regardless, although international studies are interesting, their 
cost-effectiveness data cannot be assumed to be applicable to the United States health care 
context, what has been called the “portability problem” (14). 
The most comprehensive ADHD treatment study to date is the six-site National Institute 
of Mental Health Multimodal Treatment Study of Children With ADHD (MTA Study), a 
randomized, controlled study of 579 children designed to examine the intermediate and 
long-term effectiveness of treatment options for ADHD (15, 16). The results indicated that for 
ADHD symptoms, children in the combined treatment or medication management groups 
showed significantly greater improvement than those given community care or behavioral 
treatment alone (15, 16). For children with comorbid ADHD, better outcomes were achieved 
through different treatment options, depending on the type of comorbidity (17). Thus, the MTA 
Study offers an excellent opportunity to examine the cost-effectiveness of different treatment 
modalities for children with ADHD— with and without various comorbid disorders. 
Method 
Study Design, Procedures, Subjects, and Treatments 
Five hundred seventy-nine children with ADHD, combined type, ages 7 to 9.9 years, 
were assigned to 14 months of medication management (titration followed by monthly half-hour 
visits), intensive behavioral treatment (parent, school, and child components, with therapist 
involvement gradually reduced over time), the two combined, or routine community care 
(treatments by community providers). Outcomes were assessed in multiple domains before, 
during, and at treatment endpoint (with combined treatment and medication management groups 
continuing medication at all assessment points) (18). Data were analyzed with intent-to-treat, 
random effects regression. 
Initial MTA Study Results 
All four groups showed sizable reductions in symptoms over time, with significant 
differences among them in degrees of change (15, 16). For ADHD symptoms, the groups 
receiving combined medical management and behavioral treatment and medical management 
improved significantly more than those with behavioral treatment or community care. Combined 
medical management and behavioral treatment and medical management did not differ 
significantly on direct comparisons in primary analyses, but in several instances 
(oppositional/aggressive symptoms, internalizing symptoms, teacher-rated social skills, 
parent-child relations, and reading achievement), combined medical management and behavioral 
treatment proved superior to behavioral treatment and/or community care, whereas medical 
management did not. The MTA Study’s intensive medication strategy (combined medical 
management and behavioral treatment/medical management) was superior to community care, 
despite the fact that two-thirds of community-treated subjects received similar medication during 
the study. 
Measures 
The MTA Study used a comprehensive battery of tests, drawing upon multiple 
informants across multiple outcome domains, as previously described (15). For the purposes of 
the analyses presented here, we used a composite outcome measure of treatment success to 
examine the study’s clinical relevance and practical significance (19). Thus, the end-of-treatment 
status of each subject was evaluated based on a combined overall rating, completed by both 
parents and teachers, of DSM-IV symptoms of ADHD and oppositional defiant disorder, using 
the SNAP scale, developed by Swanson and colleagues (19, 20). This instrument allowed parents 
and teachers to score each symptom on a scale with ratings of from 0 (none), 1 (just a little), 2 
(moderate), and 3 (a lot). All items were tallied and then divided by the mean number of items to 
yield an average item response, and then parent and teacher scores were combined. A low 
overall symptom severity rating (less than 1 or from “none” up to “just a little”) was found by 
receiver operating characteristic analyses to constitute a reliable criterion for treatment success. 
Logistic regression analyses were used to compare success rates for the treatments. The results 
showed that the success rates for MTA Study treatments mirrored the primary results, with the 
following proportions of children being “normalized” in each of the groups: combined medical 
management and behavioral treatment=68%, medical management=56%, behavioral 
treatment=34%, and community care=25%. Note that all such differences were statistically 
significant; that is, each treatment group differed significantly from all others in terms of rates of 
treatment success. Based on ratings of children drawn from the same classrooms, 88% of 
classroom comparison children scored in this relatively nonsymptomatic range, whereas none of 
the MTA Study children scored in this range before random assignment. We used this 
dichotomized “treatment success” variable as our outcome criterion for cost-effectiveness 
analyses. 
The revised Services for Children and Adolescents-Parent Interview (21, 22) was used by 
research staff to assess the use of mental health services across multiple service systems for all 
four treatment groups. This measure was given at 3-month intervals during treatment and 
3-6-month intervals after treatment, and we asked the families to report on the use of any 
medical and school services, community mental health services, or juvenile justice services. This 
allowed us to determine the amount and type of services used, the medication costs, and the costs 
associated with primary care versus specialty mental health services across all four randomly 
assigned groups. The reliability and validity of this scale are excellent (21, 22). 
Costs 
The societal perspective (excluding possible time lost from work by parents) was used to 
determine the costs for this study, as suggested by the Panel on Cost-Effectiveness in Health and 
Medicine (23). Thus, all of the direct costs associated with providing each of the treatment arms 
were calculated by using the real treatment costs of the MTA Study, while excluding costs 
associated with the research component of the study, such as research staff time and costs 
associated with administering the study instruments. The costs were calculated whether they 
might be paid by a patient, an insurer, or any other third party. All the costs associated with a 
given service were assumed to be the same across sites, despite the regional differences in the 
cost of living or in actual billing charges for a specific service. All costs were adjusted for 
inflation to year 2000 dollars by using the consumer price index to ensure that the results of the 
study could be understood in terms of current dollar amounts. 
Costs of the medications were calculated by using information from the National Data 
Drug File Plus (http://wwwfirstdatabank. com/knowledge_bases/nddf_plus). This database 
allows for a sampling of the average wholesale prices of all drugs from various pharmaceutical 
companies and in varying pill sizes. For example, Ritalin can be priced from either Novartis 
Pharmaceuticals or Physicians Total Care for the 5-mg, 10-mg, and 20-mg pill sizes. These 
wholesale prices present different prices per milligram; therefore, a median price was chosen for 
each medication. The following prices were used for each medication: Ritalin, Novartis, 10-mg 
pill, 0.059¢/mg; Dexedrine, Smith-Kline Beechum, 10-mg pill, 0.092¢/mg; imipramine, 
Allscripts, 50-mg pill, 0.013¢/mg; Cylert, Abbott Pharmaceutical, 37.5-mg pill, 0.046¢/mg; and 
bupropion, Geneva, 100-mg pill, 0.009¢/mg. 
The costs of the psychiatrist, psychologist, pediatrician, teacher, and teachers’ aide times 
were calculated by determining an hourly wage for these professionals based on their respective 
annual salaries. The adjusted yearly salary of the psychiatrists by using the consumer price 
index, was determined to be $142,919.80, based on data from the American Medical 
Association’s Socioeconomic Monitoring System survey (24). This salary was selected as a 
conservative estimate, given that it is within the range of pediatrician and average physician 
salaries. Psychologist-adjusted salaries were calculated as $80,523.24, based on Scheffler et al. 
(25). Teacher salaries (for those who worked in the summer treatment program) and teachers’ 
aide salaries were determined by the Bureau of Labor Statistics (26). Appropriate levels of fringe 
benefits were added to the salaries to capture total compensation. (For teachers’ aides, a rate of 
23.5% was used; for psychologists and psychiatrists, we used a rate of 27.4%. These figures 
were derived from data from the Bureau of Labor Statistics [26].) Finally, the cost of attending 
each day of the summer treatment program was calculated by using the hourly wages of the staff 
needed for the program. 
Cost-Effectiveness 
Thus, each treatment had both a cost and an outcome associated with it, with 
cost-effectiveness comprising the average total cost per child per unit of outcome (i.e., per child 
“normalized”) in each of the four groups. A measure of cost-effectiveness is the marginal or 
incremental cost-effectiveness ratio. This ratio represents the difference in the average cost 
divided by the difference in average effectiveness: 
 
This ratio represents the (incremental) cost of the new treatment for each unit of 
additional outcome. When comparing two treatments, a negative cost-effectiveness ratio means 
that one treatment costs more and is less effective than its comparison treatment. In this case, one 
treatment “dominates” the other. These figures are rarely reported because one would 
presumably never choose this treatment. 
As suggested by Kaplan and Groessl (27), for cost-effectiveness studies, sensitivity 
analysis can be conducted to determine if overall cost-effectiveness findings would have varied 
appreciably had one made different assumptions concerning any uncertain and/or influential cost 
estimates. For these purposes, we conducted two additional analyses. One was conducted with a 
lower estimate of psychologist salaries that allowed us to make a more conservative 
(lower-priced) estimate for psychosocial service costs by using the lowest costs in each category 
versus more expensive estimates of psychosocial service costs. The other analysis used a higher 
estimate of the cost of medications, with approximate retail prices instead of the more typically 
used wholesale prices. 
Comorbidity Subgroups 
Given previous evidence that the presence of a comorbid disorder can exert a substantial 
effect on costs and that MTA Study subjects showed differential treatment effects as a function 
of comorbidity patterns (17), children were categorized into one of four comorbidity profiles by 
using our previously employed grouping strategy: ADHD only (31.8%, N=184), ADHD plus 
internalizing comorbid disorder only (anxiety or depression) (14.0%, N=81), ADHD plus 
externalizing comorbid disorder only (conduct or oppositional defiant disorder) (29.5%, N=171), 
and ADHD plus both types of comorbid disorder (24.7%, N=143). Costs and cost-effectiveness 
of each treatment arm were computed both for the overall MTA Study sample and for these 
specific comorbidity groups. Note that it was not expected that the costs in the three MTA Study 
treatment groups would vary because treatment was established and limited by protocol. 
However, the effectiveness for each treatment varied as a function of comorbidity, as reported 
previously (17) and shown here in Table 1 in terms of the proportion of children “normalized” 
by each treatment for each of the comorbidity profiles. As seen in Table 1, the costs for the 
comorbidity subgroups in the community care group varied, presumably since families appear to 
have used different services as a function of their children’s comorbidity profiles. 
Results 
Costs 
Table 2 shows the costs for each treatment group and demonstrates how the costs broke 
down for each of the categories of treatment. The total cost of treatment ranged from $1,071 for 
community-treated subjects to $7,827 for 
 
Group 
Medical 
Management 
Intensive 
Behavioral 
Treatment 
Combined Medical 
Management and 
Behavioral Treatment 
Routine 
Community Care 
N % N % N % N % 
All children (N=579) 144 56 144 34 145 68 146 25 
Children with ADHD only 46 57 43 42 53 70 42 31 
Children with comorbid 
disorders 
        
ADHD plus internalizing 20 80 23 39 19 74 19 21 
ADHD plus externalizing 
disorder 
40 58 42 19 36 67 54 28 
ADHD plus both types of 
disorder 
38 39 36 39 37 62 31 16 
TABLE 1. “Normalization” Rates by Comorbidity Subgroup for Children With Attention Deficit 
Hyperactivity Disorder (ADHD) 
combined medical management and behavioral treatment subjects, with the bulk of combined 
medical management and behavioral treatment costs ($6,881) due to the behavioral treatment 
components. Pairwise comparisons showed that each treatment cost was significantly different 
from all others at the 0.05 level. 
In Table 3, the costs are shown for each of the four comorbidity profiles by treatment 
arm. The costs for the internalizing-only children, the externalizing-only children, and the 
children with both types of comorbid disorder in the medication-only group varied little, 
presumably because of the highly structured nature of the treatment protocol. Note that treatment 
costs for children in community care with conduct disorder/oppositional defiant disorder and 
both types of comorbid disorders were substantially higher ($1,204 and $976, respectively) than 
the costs for internalizing children ($718), possibly because of the increased treatment needs 
among externalizing subjects, which for these participants were handled ad libitum by families 
and their health care providers. Within each treatment group, none of these costs were 
significantly different from each other, however. 
Table 4 shows several incremental cost-effectiveness ratios comparing each of the 
different treatment arms, which were then broken down by comorbidity. The incremental 
cost-effectiveness ratio for medical management versus community care was $360, indicating 
that it cost that amount for each of the children brought to normal functioning by treating them 
through medication management, and they would not have been brought to normal functioning 
by treating them through usual care in the community. The cost-effectiveness ratio for behavioral 
treatment versus community care was $68,128, demonstrating a large increase in the cost to 
bring a child to normal functioning by treating him or her with psychosocial interventions. The 
combined cost-effectiveness ratio of medical management and behavioral treatment to 
community care was much lower—$15,993. This potentially counterintuitive finding is related 
to the fact that although combined medical management and behavioral treatment was the most 
expensive treatment, such cost was largely offset by the increase in effectiveness achieved 
through the medication component of this multimodal intervention. 
The combined medical management and behavioral treatment/medical management 
cost-effectiveness ratio was $55,253. That is, there was a large increase in price (or a sharp 
decrease in cost-effectiveness) related to adding behavioral intervention to medication 
management. The incremental cost-effectiveness ratio between the combined medical 
management and behavioral treatment and behavioral treatment alone was $2,500. Finally, the 
comparison between behavioral treatment and medical management showed a negative 
incremental cost-effectiveness ratio. In this case, the negative number indicates that the 
medication condition was both less expensive and more effective, leaving the “dominant” 
treatment remaining as the logical choice in this circumstance. 
The interior columns of Table 4 show the cost-effectiveness ratios for the same 
comparisons just mentioned but subcategorized by comorbidity. For the ADHD-only group, the 
cost-effectiveness ratios were in the same order as the previous ones. Likewise, for the ADHD 
group with internalizing difficulties, the cost-effectiveness ratios were in the same order but with 
a negative ratio for the comparison between combined medical management and behavioral 
treatment versus medical management. This was because medical management was slightly 
more effective than combined medical management and behavioral treatment, whereas combined 
medical management and behavioral treatment costs more, resulting in a negative ratio. The 
ADHD-plus-externalizing group also had a negative ratio for the behavioral treatment versus 
community care comparison, again because behavioral treatment costs more, whereas 
community care was slightly more effective numerically. We did not report computed negative 
ratios. In most of these cases, one treatment was both more costly and less effective than the 
alternative. Presumably, one would never choose a less effective, more expensive treatment over 
another. In the case of the other ratios, the monetary values reported gave the relative expenses 
of choosing one treatment over another, and it remains a decision by policy makers, patients, or 
administrators to decide how much is an acceptable level of cost to incremental benefit. 
Figure 1 illustrates the relationships among the four treatment groups, with outcomes 
portrayed on the vertical axis and costs on the horizontal axis. Treatment as usual (community 
care) is represented as the origin, and so the slope of the lines linking the origin to each point 
represents the incremental cost-effectiveness ratio for that treatment. 
Variable 
Cost per Child per Treatment Arm ($) 
Medical 
Management 
Intensive 
Behavioral 
Treatment 
Combined Medical 
Management and 
Behavioral Treatment 
Routine 
Community Care 
Total 1,180 6,988 7,827 1,071 
Components of cost     
Medication 624 104 538 222 
Medication visit 393 34 408 91 
Psychosocial therapy 163 6,850 6,881 757 
TABLE 2. Cost per Child per Treatment Arm ($) for Children With Attention Deficit Hyperactivity 
Disorder (ADHD) During 14 Months of Treatment 
  
Child Diagnosis 
Cost per Child per Treatment Arm ($) 
Medical 
Management
Intensive Behavioral 
Treatment 
Combined Medical 
Management and 
Behavioral Treatment 
Routine 
Community Care
ADHD only 1,079 7,176 7,438 1,131 
ADHD plus internalizing 
disorder 
1,231 6,447 8,138 718 
ADHD plus externalizing 
disorder 
1,245 7,080 8,083 1,204 
ADHD plus both types of 
disorder 
1,206 7,003 7,977 976 
TABLE 3. Cost per Child per Treatment Arm ($) by Comorbidity Subgroup for Children With Attention 
Deficit Hyperactivity Disorder (ADHD) During 14 Months of Treatment 
Statistical Significance 
Each point estimate on Figure 1 is surrounded by a “cloud” of points. These reflect the 
fact that the mean cost and effects for each treatment are an estimate and are subject to sampling 
error. The additional points were generated by using bootstrapping and capture the uncertainty 
surrounding each estimate. One can see that the differences in the three treatments offered 
represent more than sampling error and that the incremental cost-effectiveness ratios for each can 
be meaningfully distinguished. This finding is confirmed by confidence intervals for each of the 
incremental cost-effectiveness ratios (available from the first author). These intervals generally 
indicate that the analyses were sufficiently powered. 
Sensitivity Analysis 
There was uncertainty in some of the assumptions involved in estimating the costs of 
behavioral treatment. For example, we had widely varying estimates of psychologist salaries, 
depending upon the source: the Bureau of Labor Statistics reported that psychologist salaries are 
a mean of $45,000, quite different from that ($80,000) found in other sources (25). By using this 
lower estimate for salary instead, we arrived at a more conservative estimate of the cost of some 
of the psychosocial components. However, this did not change the cost-effectiveness ratios 
significantly. When we reexamined Table 4 costs, these analyses revealed that there was a 
$1,178 decrease in the cost-effectiveness ratio when we compared combined medical 
management and behavioral treatment to community care, an $861 increase in medical 
management compared to community care, a $5,539 decrease in the comparison 
of behavioral treatment to community care, and a $6,298 decrease in the comparison of the 
cost-effectiveness ratio for combined medical management and behavioral treatment to medical 
management group (data available upon request from the first author). These ratios represent the 
psychosocial costs at their lowest estimates but did not appreciably change the findings presented 
earlier. 
The second sensitivity analysis used retail prices for medications instead of wholesale 
prices. The marked-up retail prices were estimated at 40% higher than wholesale prices, as 
estimated by Danzon (28). Of interest, this analysis also did not change the cost-effectiveness 
ratios considerably, except in the comparison between medical management and community 
care. When we looked again at Table 4 costs for reference, the comparison of medical 
management to community care showed a $532 increase, which more than doubled the 
cost-effectiveness ratio but still showed a relatively cost-effective alternative treatment for 
medical management versus behavioral treatment and combined medical management and 
behavioral treatment. The other ratios showed similar patterns as the original analysis, with the 
cost-effectiveness ratio for behavioral treatment to community care at $67,683, combined 
medical management and behavioral treatment to community care at $16,314, combined medical 
management and behavioral treatment to medical management at $55,043, combined medical 
management and behavioral treatment to behavioral treatment at $3,019, and behavioral 
treatment to medical management still showing medical management as a dominant treatment. 
Discussion 
Our findings suggest that the ADHD treatment costs of medication, behavioral treatment, 
and combined therapies are within the range of costs for many other chronic illnesses (5, 6), 
although within these three treatments, fourfold 
 
Treatment 
Cost-Effectiveness Estimate per Child ($) 
Total 
ADHD 
Only 
ADHD Plus 
Internalizing 
Disorder 
ADHD Plus 
Externalizing 
Disorder 
ADHD Plus 
Both Types of 
Disorder 
Medical management versus community 360 —a 870 140 988
Intensive behavioral treatment versus 
community care 
68,128 55,418 31,690 —b 26,480 
Combined medical management and 
behavioral treatment versus community 
     
15,993 16,230 14,099 17,691 15,208 
Combined medical management and      
medical management 55,253 47,844 —b 74,597 29,840 
Combined medical management and      
intensive behavioral treatment 2,500 936 4,896 2,106 4,184 
Intensive behavioral treatment versus —b —b —b —b —b 
a Medical management “dominated” community care in the “ADHD Only” subgroup, i.e., it was less 
expensive and more effective. 
b The absence of numbers indicates that one treatment was both more expensive and less effective, making it an 
untenable choice for a treatment of this duration. 
TABLE 4. Cost-Effectiveness Estimates per Child ($) by Comorbidity Subgroup for Children With 
Attention Deficit Hyperactivity Disorder (ADHD) During 14 Months of Treatment 
variations were seen. Medical management (the costs of both medication and physician visits) 
was the least expensive ($1,180), followed by behavioral treatment ($6,988), at over five times 
the cost of medication, and combined medical management and behavioral treatment ($7,827), at 
over six times the cost of medication alone. 
As one would expect, within the three MTA Study treatment arms, the cost of the 
medical management treatment component was equivalent to the same medication 
treatment-related costs within the combined medical management and behavioral treatment arms 
(Table 2). Similarly, the cost of behavioral treatment was the same as the same components 
within the combined medical management and behavioral treatment arm. This equivalence was 
as study planners intended, of course, because the combined medical management and 
behavioral treatment components were based on the same treatments, in type and intensity, as the 
medical management and behavioral treatment arms. The somewhat lower cost ($86) of 
medication in the combined medical management and behavioral treatment arm versus the 
medical management group reflects the fact that the condition of the subjects in combined 
medical management and behavioral treatment was maintained with somewhat lower doses of 
medication than the subjects in medical management, as noted in our first report (15). In contrast, 
the actual cost for physician visits did not differ between these two arms because the protocol 
required monthly visits to the physician to monitor the medication. Also of note are the 
dramatically smaller costs associated with medication treatment in the community care group. 
Physician visit costs within the community care group were less than one-fourth of the costs of 
the medical management and combined medical management and behavioral treatment arms, and 
medication costs were roughly one-third of the cost of the medical management and combined 
medical management and behavioral treatment arms. Both findings reflect the substantially lower 
doses used by community physicians for community-treated subjects, as well as the much less 
frequent monitoring (generally once per month versus two times per year for community care), 
as noted in our first report (16). 
 
FIGURE 1. Incremental Cost-Effectiveness ($) of Alternative Treatments Relative to Routine Community 
Care for Children With Attention Deficit Hyperactivity Disorder (ADHD) During 14 Months of Treatment 
As has been previously reported by others, community-treated children with ADHD with 
certain comorbid disorders do show increased costs for treatment, with the greatest costs seen in 
children with ADHD plus a disruptive (externalizing) disorder ($1,204) showing an increase 
over the costs of treating ADHD children with no comorbid disorder ($1,131) and ADHD 
children with an internalizing disorder (depression or anxiety) only ($718) (Table 3). The costs 
of community-treated children with both types of comorbid disorder were actually slightly lower 
(roughly $230) than for ADHD children with an externalizing disorder. Of note, total costs of 
care for ADHD children with the various comorbid disorders treated with medical management, 
behavioral treatment, and combined medical management and behavioral treatment did not differ 
meaningfully, as one would expect given the structured nature of the MTA Study treatment 
protocols. 
Cost-effectiveness findings comparing the various treatments yielded quite dramatic 
findings in terms of how much it costs to bring additional children to normal functioning. Under 
circumstances in which one treatment has been shown to be more effective than another but is 
also more expensive, the total column in Table 4 shows how much it costs per child to bring 
additional children to normal functioning with the more effective treatment. Thus, medical 
management, more effective but also more costly than community care, costs only $360 for each 
of the additional children “normalized”—a fairly modest cost for dramatic gains in the possible 
number of children effectively treated. However, where only small differences in effectiveness 
were seen between two treatments, the more intensive, more effective treatment costs much more 
per additional child “normalized,” such as seen in the comparison between combined medical 
management and behavioral treatment and medical management, with the former costing over 
$55,253 more per additional child “normalized.” Such findings suggest that medication 
treatment, although as effective as combined medical management and behavioral treatment in 
terms of overall percentages of children yielding treatment success, might be the more 
economical alternative in routine treatments for children with ADHD. Other cost-effective 
comparisons, such as medical management versus behavioral treatment, are not meaningful in 
cost-effectiveness terms, since medical management is both more effective and less expensive 
than behavioral treatment (Table 2). These results show medical management to be the 
“dominant” treatment. 
The actual cost differentials vary, however, depending upon the children’s comorbidity 
status, as seen in Table 4. In contrast to the total cost findings, treating children with ADHD plus 
both types of comorbid disorder with combined medical management and behavioral treatment 
versus medical management costs somewhat less than previously thought (an incremental 
cost-effectiveness ratio of $29,840), suggesting that it is most cost-effective to target combined 
treatment to children with both types of comorbid disorder. In contrast, combined medical 
management and behavioral treatment for ADHD children with externalizing comorbid disorder 
only is not much more effective than medical management alone; thus, costs per additional child 
“normalized” by using combined medical management and behavioral treatment are far greater 
(an incremental cost-effectiveness ratio of $74,597) than the cost of the same treatment for 
children with ADHD plus both types of comorbid disorder— $29,840—again, compared to 
medical management alone. 
Limitations 
Of concern is the possibility that some of our cost estimates may be incorrect. In 
particular, given the implications for the expense of behavioral and combined treatments, we 
conducted sensitivity analyses examining a range of lower costs associated with behavioral 
treatment components, as well as adding in the costs of medication treatment for the subset of 
children in the behavioral treatment group who received medication. These analyses did not yield 
appreciably different results. In general, where there was uncertainty about cost assumptions, we 
biased our estimates in favor of the behavioral treatment so that behavioral treatment costs could 
be kept as low as possible. The results, favoring the cost-effectiveness of the medical 
management condition, were strengthened in light of this bias in favor of the behavioral 
treatment condition. Of course, it should be noted that the particular psychosocial treatment 
package was designed within the context of our trial, and other or less intensive behavioral 
approaches might be more comparable in terms of cost-effectiveness ratios. 
Of importance, given our 14-month outcome analyses, our findings did not address the 
potential longer-term cost-effectiveness of treatment or the broader societal costs incurred as a 
result of ADHD, such as the condition’s impact on parental work absences and loss of income, 
the costs of special education services and other social services, including the juvenile justice 
system. Although not examined in the context of this article, they are nonetheless a part of the 
cost of the illness, if not the cost of treatment. 
Finally, it should be noted that, by definition, cost-effectiveness evaluations based on 
purely clinical outcomes, such as responder rates defined by SNAP scale ratings (19, 20), do not 
fully address the range of possible comparisons across different types of outcomes. Although our 
SNAP ratings did have the advantage of being a composite of both parents’ and teachers’ reports, 
had we chosen different types of outcomes—such as overall impairment, social skills, or 
consumer satisfaction—quite different cost-effectiveness ratios may have resulted. Analyses 
comparing cost-effectiveness ratios across these different types of outcomes will be described in 
future reports. 
Another alternative outcome measure—the cost per number of quality-adjusted life-years 
gained—has been used widely in health technology assessments because it is commonly believed 
to enable such comparisons between programs (23). In the absence of direct evidence from the 
MTA Study on health-related utility weights associated with the treatments investigated, we 
employed the approach adopted by Lord and Paisley (29) in the United Kingdom, which is very 
similar to the estimates of Gilmore and Milne (13). Hence, we assume, based on the EQ-5D 
Quality of Life Scale (30), that without treatment, children would be in health state 11211 (utility 
weight=0.883), indicating some difficulties performing their usual activities, and that treatment 
responders would be returned to full health (health state 11111, with a utility weight of 1.000). 
These calculations yielded a cost of $3,077 per quality-adjusted life-year for medical 
management (over community care) and $472,248 per quality-adjusted life-year for combined 
medical management and behavioral treatment (over medical management; $136,692 if 
compared with community care only), with intensive behavioral treatment dominated by medical 
management. These figures provide an estimate of the dimension of the incremental cost per 
quality-adjusted life-year for the medication management and combined medication management 
and behavioral treatment strategies. 
By way of caution, we note that there is no universally applicable cost-effectiveness 
benchmark for quality-adjusted life-years. To date, for instance, internationally used thresholds 
have varied widely, to an extent higher than might be explained by economic variables (31). 
Furthermore, a review of the willingness-to-pay literature (32) suggests that these thresholds 
may have been arbitrarily set at levels substantially below those found in value-of-life studies 
using the contingent-valuation or revealed-preference methods. 
For comparative purposes, however, it can be noted that children with ADHD incur 
similar medical costs as children with asthma (5, 6). And in view of the greater costs incurred by 
ADHD children than healthy children for medical costs ($1,000–2,000 per year) (7–9) and for 
auto accidents ($3,000) (4) and their increased use of other expensive programs (special 
education services, juvenile justice, etc.), the modest incremental costs for more effective versus 
less effective programs (e.g., $360 for intensive medication management versus standard 
community care) seem easily justified and potentially a wise investment. 
In summary, our findings suggest that carefully monitored medication treatment, 
although not quite as effective as the combination of medication and behavioral treatment, is 
likely to be more cost-effective in routine treatments for children with ADHD, particularly those 
without comorbid disorders. For some children with comorbid disorders, it may be relatively 
cost-effective to provide combination treatment. By way of caution, it should be noted that 
although medication management may be the most cost-effective option for achieving treatment 
success (as defined by symptom improvement) in children, that may not necessarily be the goal 
of families. For instance, other things may be taken into account, such as side effects, the 
family’s overall feelings about the causes of the disorder in question, and their relative comfort 
and satisfaction with the treatment approach. These alternative outcome areas will be the subject 
of future reports. 
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